BRIEF—JCR and Sumitomo Pharma to co-promote Izcargo in Japan

Japanese drugmakers JCR Pharmaceuticals and Sumitomo Pharma have concluded a co-promotion agreement for Izcargo (pabinafusp alfa) IV Infusion 10mg in Japan.

This is a recombinant therapeutic for mucopolysaccharidosis type II, also knwn as Hunter syndrome, currently sold by JCR.

From April 24, 2023, JCR and Sumitomo Pharma will jointly engage in information dissemination activities for Izcargo to healthcare professionals.

JCR will continue to manufacture and sell the product.

Sumitomo Pharma will make an undisclosed upfront payment to JCR upon execution of the agreement.

Sumitomo Pharma will record the consideration for promotion received from JCR as revenue.

Sumitomo Pharma and JCR will contribute further to the treatment of patients with mucopolysaccharidosis type II (Hunter syndrome) through the co-promotion of the product.